Literature DB >> 8148228

Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants.

H Bagheri1, P Picault, L Schmitt, G Houin, M Berlan, J L Montastruc.   

Abstract

The pharmacokinetic parameters and the time course of the effect after acute oral administration of yohimbine on salivary secretion in patients treated with tricyclic antidepressants were investigated. Yohimbine (10 mg) increased both salivary outflow and plasma noradrenaline levels for 4 h. Pharmacokinetic parameters (t1/2, tmax, Cmax and AUCexp) and plasma concentrations of noradrenaline were higher in patients treated with tricyclic antidepressants than in controls. At this dose, yohimbine induced a relatively large number of side effects. A lower dose (4 mg) increased salivary secretion for 3 h without any side effects in patients treated with tricyclic antidepressants but not in healthy volunteers. These data describe an interaction between yohimbine and tricyclic antidepressants and thus show that a relatively low dose (4 mg) of yohimbine could be useful in the treatment of dry mouth due to tricyclic antidepressants.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8148228      PMCID: PMC1364719          DOI: 10.1111/j.1365-2125.1994.tb04248.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Yohimbine bioavailability in humans.

Authors:  S K Guthrie; M Hariharan; L J Grunhaus
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Yohimbine increases human salivary secretion.

Authors:  E Chatelut; Y Rispail; M Berlan; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

3.  The action of sedatives on brain stem oculomotor systems in man.

Authors:  H Norris
Journal:  Neuropharmacology       Date:  1971-03       Impact factor: 5.250

Review 4.  Yohimbine: a pharmacological probe for study of the alpha 2-adrenoreceptor.

Authors:  M R Goldberg; D Robertson
Journal:  Pharmacol Rev       Date:  1983-09       Impact factor: 25.468

5.  Effects of yohimbine on submaxillary salivation in dogs.

Authors:  P Montastruc; M Berlan; J L Montastruc
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

6.  Sub-nanogram analysis of yohimbine and related compounds by high-performance liquid chromatography.

Authors:  J A Owen; S L Nakatsu; M Condra; D H Surridge; J Fenemore; A Morales
Journal:  J Chromatogr       Date:  1985-08-09

7.  The pharmacokinetics of yohimbine in man.

Authors:  J A Owen; S L Nakatsu; J Fenemore; M Condra; D H Surridge; A Morales
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomipramine.

Authors:  L Lacomblez; G Bensimon; F Isnard; B Diquet; Y Lecrubier; A J Puech
Journal:  Clin Pharmacol Ther       Date:  1989-03       Impact factor: 6.875

9.  [Determination of yohimbine in serum by high performance liquid chromatography].

Authors:  R Chiba; Y Isii
Journal:  Yakugaku Zasshi       Date:  1990-04       Impact factor: 0.302

10.  THE INCREASE IN THE TOXICITY OF YOHIMBINE INDUCED BY IMIPRAMINE AND OTHER DRUGS IN MICE.

Authors:  R M QUINTON
Journal:  Br J Pharmacol Chemother       Date:  1963-08
View more
  1 in total

Review 1.  Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states.

Authors:  H M Bryson; M I Wilde
Journal:  Drugs Aging       Date:  1996-06       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.